Daniel Hart - Avid Bioservices Chief Officer
| CDMO Stock | USD 12.49 0.01 0.08% |
Executive
Mr. Daniel R. Hart is Chief Financial Officer of the Company, effective August 1, 2018. He has served as Chief Financial Officer since August 1, 2018 and has over 20 years of finance and accounting experience. Mr. Hart is responsible for overseeing and managing all of our accounting and finance functions. Prior to joining us, Mr. Hart served as Chief Financial Officer of ENO Holdings, Inc., a family of companies focused on the residential real estate market with offerings spanning brokerage, franchisor, property management, title and escrow services. While with ENO Holdings, he helped optimize the groups accounting and finance department with a focus on establishing repeatable processes in the areas of financial statements, operating plans, cash forecasts and organization budgets. Prior to that position, Mr. Hart served as Senior Vice President, Chief Financial Officer and Assistant Secretary at SMA, a 100 million private equity owned management consulting firm that was previously a Nasdaqlisted company. During his time at SMA, which included several financial leadership positions of increasing responsibility, he was responsible for overseeing financial stewardship and played a central role in various financial transactions and corporate acquisitions since 2018.
| Age | 52 |
| Tenure | 7 years |
| Phone | 714 508 6100 |
| Web | https://www.avidbio.com |
Daniel Hart Latest Insider Activity
Tracking and analyzing the buying and selling activities of Daniel Hart against Avid Bioservices stock is an integral part of due diligence when investing in Avid Bioservices. Daniel Hart insider activity provides valuable insight into whether Avid Bioservices is net buyers or sellers over its current business cycle. Note, Avid Bioservices insiders must abide by specific rules, including filing SEC forms every time they buy or sell Avid Bioservices'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Daniel Hart over six months ago Acquisition by Daniel Hart of 2120 shares of Avid Bioservices subject to Rule 16b-3 |
Avid Bioservices Management Efficiency
The company has return on total asset (ROA) of (0.0305) % which means that it has lost $0.0305 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1584) %, meaning that it created substantial loss on money invested by shareholders. Avid Bioservices' management efficiency ratios could be used to measure how well Avid Bioservices manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Tim Randall | MeiraGTx Holdings PLC | N/A | |
| Monique Silva | AnaptysBio | N/A | |
| Daniel Wilson | Dyne Therapeutics | 53 | |
| Paul Barsanti | Ideaya Biosciences | N/A | |
| Minji MBA | Mineralys Therapeutics, Common | N/A | |
| James MD | AnaptysBio | 62 | |
| Alethia Young | Bicycle Therapeutics | 45 | |
| JD Esq | Ideaya Biosciences | 52 | |
| Jolanda Howe | Mirum Pharmaceuticals | N/A | |
| Robert MD | Crinetics Pharmaceuticals | N/A | |
| Stu Dorman | Ideaya Biosciences | N/A | |
| Michael PharmD | Kalvista Pharmaceuticals | 45 | |
| Francine Zelaya | Ideaya Biosciences | N/A | |
| Pamela Vig | Mirum Pharmaceuticals | 54 | |
| Martin Dahl | AnaptysBio | N/A | |
| Yan MBA | Adagene | 50 | |
| JeanLuc Girardet | Mirum Pharmaceuticals | N/A | |
| Ronan JD | Lyra Therapeutics | 52 | |
| Xiaohong She | Adagene | 58 | |
| Danielle Bradbury | Mineralys Therapeutics, Common | N/A | |
| Dana MD | Crinetics Pharmaceuticals | 69 | |
Management Performance
| Return On Equity | -1.16 | ||||
| Return On Asset | -0.0305 |
Avid Bioservices Leadership Team
Elected by the shareholders, the Avid Bioservices' board of directors comprises two types of representatives: Avid Bioservices inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avid. The board's role is to monitor Avid Bioservices' management team and ensure that shareholders' interests are well served. Avid Bioservices' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avid Bioservices' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shelley Fussey, Vice President - Intellectual Property | ||
| Daniel Hart, Chief Officer | ||
| Mark JD, General VP | ||
| Oksana Lukash, Vice People | ||
| Prof Brekken, Medical Advisor | ||
| Harold MD, Medical Advisor | ||
| Prof Schroit, Medical Advisor | ||
| Matthew Kwietniak, Chief Officer | ||
| Richard Richieri, Chief Officer | ||
| Tracy Kinjerski, VP Operations |
Avid Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Avid Bioservices a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.16 | ||||
| Return On Asset | -0.0305 | ||||
| Profit Margin | (1.01) % | ||||
| Operating Margin | (0.06) % | ||||
| Current Valuation | 971.01 M | ||||
| Shares Outstanding | 63.96 M | ||||
| Shares Owned By Insiders | 1.13 % | ||||
| Shares Owned By Institutions | 98.87 % | ||||
| Number Of Shares Shorted | 11.62 M | ||||
| Price To Earning | 10.76 X |
Pair Trading with Avid Bioservices
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Avid Bioservices position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Avid Bioservices will appreciate offsetting losses from the drop in the long position's value.Moving against Avid Stock
| 0.51 | MBRX | Moleculin Biotech | PairCorr |
| 0.49 | MDXG | MiMedx Group | PairCorr |
| 0.41 | VANI | Vivani Medical | PairCorr |
| 0.37 | MBIO | Mustang Bio | PairCorr |
The ability to find closely correlated positions to Avid Bioservices could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Avid Bioservices when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Avid Bioservices - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Avid Bioservices to buy it.
The correlation of Avid Bioservices is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Avid Bioservices moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Avid Bioservices moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Avid Bioservices can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avid Bioservices. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Avid Stock, please use our How to Invest in Avid Bioservices guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avid Bioservices. If investors know Avid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avid Bioservices listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Avid Bioservices is measured differently than its book value, which is the value of Avid that is recorded on the company's balance sheet. Investors also form their own opinion of Avid Bioservices' value that differs from its market value or its book value, called intrinsic value, which is Avid Bioservices' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avid Bioservices' market value can be influenced by many factors that don't directly affect Avid Bioservices' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avid Bioservices' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avid Bioservices is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avid Bioservices' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.